(CercleFinance.com) – Quantum Genomics rose by more than 8% on the Paris Stock Exchange on Monday after announcing its intention to present the results of its phase III study in resistant hypertension at the annual congress of the American Heart Association, to be held in November in Chicago.
The biopharmaceutical company will unveil the results of this hard-to-treat and resistant hypertension trial on November 4 in a so-called ‘late-breaking’ session by the study’s principal investigator, Professor Bakrir, professor of medicine at the University of Chicago.
Bruno Besse, the medical director of Quantum, welcomes in a press release this meeting which must take place in a ‘prestigious’ framework, which according to him validates the interest of the scientific community for the approach of the company in this pathology where there is currently little or no therapeutic alternative.
The results of this study should constitute a ‘first key step’ with a view to filing the registration dossier with the American and European authorities.
This study recruited 515 patients with difficult to treat or resistant hypertension, who were randomized to 69 hospitals in Europe, Canada, the United States and Latin America.